【摘要】 本研究探讨儿童急性淋巴细胞性白血病中SLC25A38表达水平及其临床意义。以23例初治儿童急性淋巴细胞白血病患儿作为实验组,10例非恶性血液病患儿作为对照组。通过Western blot及实时荧光定量RT-PCR方法检测SLC25A38在蛋白和mRNA水平的表达变化。结果表明:23例实验组中SLC25A38蛋白阳性的有8例,阳性率34.78%,10例对照均未检测出SLC25A38蛋白;ALL患儿中SLC25A38蛋白阳性组mRNA的相对表达量为0.4673±0.05344,阴性组为1.296±0.2517;蛋白阳性组较阴性组SLC25A38 mRNA的表达量明显降低(P=0.001);蛋白阴性组与对照组比较表达量无统计学差异(P=0.1097);临床资料分析发现,蛋白阳性组与阴性组在性别比例、免疫分型、初诊时外周血白细胞数、乳酸脱氢酶之间差异具有统计学意义(P<0.05)。结论:SLC25A38蛋白作为一种新发现的蛋白,在初诊儿童急性白血病细胞中过表达,有可能作为急性白血病的一种新的分子标志和潜在的治疗靶点。更多还原

【Abstract】 This study was aimed to investigate the SLC25A38 expression in pediatric patients with acute lymphoblastic leukemia( ALL) and its clinical significance. A total of 23 newly diagnosed ALL pedictric patients were enrolled in test group,10 pediatric patients with non-hematologic malignancies were selected as control group. The expression in protein and mRNA levels of SLC25A38 were detected by Western blot and real-time PCR respectively. The results showed that the SLC25A38 protein was positive in 8 of 23 pediatric ALL patients( 34. 78%),while no positive case was found in 10 controls. The relative expression level of SLC25A38 mRNA was 0. 4673 ± 0. 05344 in SLC25A38-protein positive group of ALL patients,while that was 1. 296 ± 0. 2517 in SLC25A38-protein negative group of ALL patients. The expression level of SLC25A38 mRNA in SLC25A38-protein positive group was significantly lower than that in negative group( P = 0. 001). No statistically significant difference was found in comparison of SLC25A38-protein negative group of ALL patients with the control group( P = 0. 1097). The analysis of clinical data showed that there were significantly differences in sex,immunophenotype,initial peripheral white blood cell count and LDH between the SLC25A38-protein positive and SLC25A38-protein negative groups( P < 0. 05). It is concluded that as a novel protein,SLC25A38 highly expressed in pediatric ALL patients,indicating that SLC25A38 may serve as a molecular marker and potential therapeutic target for acute lymphoblastic leukemia in children.更多还原